Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Jan 11 2021 Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021 Dec 30 2020 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021 Dec 22 2020 Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures Dec 21 2020 Cyclacel Pharmaceuticals Announces That Brian Schwartz, M.D. Was Elected to Its Board of Directors Nov 11 2020 Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results Nov 05 2020 Cyclacel Pharmaceuticals to Release Third Quarter Financial Results Oct 26 2020 Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020 Oct 23 2020 Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer Oct 05 2020 Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference Sep 21 2020 Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020 Aug 12 2020 Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results Aug 05 2020 Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results Jul 13 2020 Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer May 12 2020 Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results May 05 2020 Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results Apr 24 2020 Cyclacel Announces Closing of $20 Million Public Offering Apr 21 2020 CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING Apr 20 2020 Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease Apr 14 2020 Cyclacel Announces Reverse Stock Split Feb 26 2020 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Feb 19 2020 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results Feb 03 2020 Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference Jan 13 2020 Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020 Jan 06 2020 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco Dec 09 2019 Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Jan 11 2021 Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021 Dec 30 2020 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021 Dec 22 2020 Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures Dec 21 2020 Cyclacel Pharmaceuticals Announces That Brian Schwartz, M.D. Was Elected to Its Board of Directors Nov 11 2020 Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results Nov 05 2020 Cyclacel Pharmaceuticals to Release Third Quarter Financial Results Oct 26 2020 Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020 Oct 23 2020 Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer Oct 05 2020 Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference Sep 21 2020 Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020 Aug 12 2020 Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results Aug 05 2020 Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results Jul 13 2020 Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer May 12 2020 Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results May 05 2020 Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results Apr 24 2020 Cyclacel Announces Closing of $20 Million Public Offering Apr 21 2020 CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING Apr 20 2020 Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease Apr 14 2020 Cyclacel Announces Reverse Stock Split Feb 26 2020 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Feb 19 2020 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results Feb 03 2020 Cyclacel Pharmaceuticals to Present at the 2020 BIO CEO & Investor Conference Jan 13 2020 Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020 Jan 06 2020 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco Dec 09 2019 Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
Jan 11 2021 Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021
Dec 22 2020 Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures
Dec 21 2020 Cyclacel Pharmaceuticals Announces That Brian Schwartz, M.D. Was Elected to Its Board of Directors
Oct 26 2020 Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020
Oct 23 2020 Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer
Oct 05 2020 Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference
Sep 21 2020 Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020
Jul 13 2020 Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer
Apr 20 2020 Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease
Jan 13 2020 Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020
Dec 09 2019 Cyclacel’s CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias
